Physician profile
David Dobies
NPI 1689642415
$7,001.92
in general payments reported to CMS, 2019-2025
41 companies · $471 in 2025
The $471 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,139 · 2020: $15.38 · 2021: $714 · 2022: $877 · 2023: $1,048 · 2024: $739 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.57 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,555.24 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir, Perclose Prostyle |
| Astrazeneca Pharmaceuticals Lp | $467.03 | 2019-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.96 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $337.06 | 2021-2024 | Xarelto |
| Medtronic, INC. | $326.01 | 2021-2025 | Micra, Export Ap, Telescope |
| Abiomed | $233.48 | 2023-2025 | Impella |
| Merck Sharp & Dohme LLC | $217.34 | 2021-2024 | Verquvo |
| Novo Nordisk INC | $216.03 | 2023-2024 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $190.73 | 2019-2024 | Lifevest |
| Edwards Lifesciences Corporation | $182.69 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Amgen INC. | $168.81 | 2019-2022 | |
| Pfizer INC. | $148.99 | 2019-2025 | |
| Cordis US Corp. | $148.54 | 2024 | Mynx Control |
| Astellas Pharma US INC | $136.60 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $134.45 | 2019-2025 | Uptravi, Opsynvi, Opsumit |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dobies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.